Small Molecules

10 Dec 2017 Medivir announces Janssen decision to terminate its simeprevir license effective June 2018
10 Dec 2017 Oncopeptides presented interim data from the ongoing phase II study HORIZON with Ygalo® (melflufen) at the 59th Annual Meeting of ASH today
10 Dec 2017 AstraZeneca’s CALQUENCE® (acalabrutinib) Demonstrates Activity in Relapsed or Refractory Mantle Cell Lymphoma Trial
09 Dec 2017 Amphivena Presents Preclinical Data at ASH That Points to a Potentially New Treatment for MDS Patients
09 Dec 2017 IMBRUVICA® (ibrutinib) Pooled Analysis Suggests Benefit in Progression-Free Survival (PFS) at 3.5 Years in Patients with Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL)
09 Dec 2017 Sprycel (dasatinib) Added to Standard Chemotherapy Demonstrates Three-Year Survival Benefit in Pediatric Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
08 Dec 2017 MediciNova Announces Positive Top-Line Results from the Clinical Trial of MN-166 (ibudilast) in ALS
08 Dec 2017 Radius Investigational Drug Elacestrant (RAD1901) Continues to Show Promise in Advanced ER+ / HER2- Breast Cancer at the 2017 San Antonio Breast Cancer Symposium
08 Dec 2017 Talazoparib Significantly Extends Progression-Free Survival in Phase 3 EMBRACA Trial of Patients with Metastatic Breast Cancer
07 Dec 2017 BlackThorn Therapeutics Presents Preclinical and Clinical Data From Its First-in-Class NOPR Antagonist at American College of Neuropsychopharmacology Annual Meeting
07 Dec 2017 Sage Therapeutics Reports Positive Top-line Results from Phase 2 Placebo-Controlled Trial of SAGE-217 in Major Depressive Disorder
07 Dec 2017 H3 Biomedicine Presents Preclinical Data on Novel ERα Antagonist at San Antonio Breast Cancer Symposium
07 Dec 2017 Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2017 San Antonio Breast Cancer Symposium
07 Dec 2017 Novartis Kisqali® is first and only CDK4/6 inhibitor to show superior median PFS compared to oral endocrine therapy as first-line treatment in a prospective, randomized Phase III trial dedicated to...
06 Dec 2017 Minerva Neurosciences Announces Enrollment of First Patient in Phase 2b Trial of Seltorexant (MIN-202) in Patients With Insomnia Disorder
06 Dec 2017 Arch Biopartners Announces Completion of GMP Manufacturing of AB569 and Start Date of Phase I Trial
06 Dec 2017 Genoscience Pharma receives FDA approval for Phase Ib/IIa study of GNS561 in liver cancer
05 Dec 2017 Galectin Therapeutics Announces Results from Phase 2b NASH-CX Trial
05 Dec 2017 Novan Announces First Patient Dosed in Phase 1b Atopic Dermatitis Trial with SB414
05 Dec 2017 IMBRUVICA® (ibrutinib) Plus Rituximab Phase 3 iNNOVATE Trial in Rare Waldenström's Macroglobulinemia Met Primary Endpoint
05 Dec 2017 Realm Therapeutics Announces First Patient Dosed in Phase 2 Study of PR022 for the Treatment of Atopic Dermatitis
05 Dec 2017 Adamis Pharmaceuticals Announces Submission of Investigational New Drug (IND) Application to the FDA for New Product Candidate for the Treatment of Opioid Overdose
05 Dec 2017 Idorsia announces collaboration with Janssen Biotech on aprocitentan (ACT-132577)
04 Dec 2017 Ironwood Reports Top-line Phase IIa Data for IW-1973 Demonstrating Positive Cardiovascular, Metabolic and Endothelial Effects
04 Dec 2017 Foresee Pharmaceuticals Announces Results from Phase 1 Clinical Studies

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing